Combioxin Announces an Oral Presentation on CAL02 clinical results at ESICM 2018

October 18, 2018
Combioxin SA

Geneva, Switzerland, 18 October 2018 – Combioxin SA, a clinical-stage biotechnology company focused on the development of innovative treatments for severe and resistant infections, announced today that first-in-human clinical results with CAL02 in severe pneumonia patients in ICU will be presented during the ESICM’s annual congress, LIVES 2018, taking place October 20-24, 2018 in Paris, France.


Press Release available here: